Subscribe to RSS
DOI: 10.1055/a-0952-6385
Rheumatologische Autoimmundiagnostik
Antikörperdiagnostik zur Klassifikation, Diagnose- und TherapieentscheidungNew aspects on autoantibodies for classification, diagnosis and therapy within rheumatologyPublication History
Publication Date:
04 February 2020 (online)
Was ist neu?
Paradigmenwechsel in der Klassifikation des systemischen Lupus erythematodes Der Nachweis der antinukleären Antikörper oberhalb des Grenzwerts ist Eingangskriterium für die Klassifikation des SLE. Diese Klassifikation beinhaltet 10 unterschiedliche Domänen mit unterschiedlicher Wertigkeit, wobei 10 Punkte für die SLE-Klassifikation erforderlich sind.
Antiphospholipidsyndrom Aktuelle Empfehlungen zum Antiphospholipidsyndrom differenzieren serologisch ein Hochrisiko- (u. a. triple-positiv, Nachweis des Lupus-Antikoagulans) und Niedrigrisiko-Profil (isolierte Anti-Cardiolipin- oder -beta-2-Glykoprotein-I-Antikörper) und begründen damit z. T. Prophylaxe- und Therapieempfehlungen nach arteriellen und venösen Verschlüssen sowie geburtshilflichen APS-Komplikationen.
Abstract
Recent advances in rheumatology indicate increased relevance of autoantibodies. In this regard, positive ANA are now required as entrance criterium for the first EULAR/ACR classification criteria of SLE. Importantly, ANA diagnostic with detection of isolated anti-dense fine speckled antibodies (DSF-70) need consideration since their unique detection has been identified to exclude largely an autoimmune disease. Thus, highly qualified ANA diagnostic preferably on Hep-2 cell lines is a prerequisite of reliable diagnostics.
Recent recommendations for the management of antiphospholipid syndrome define high versus low risk seroprofiles which also guide primary and secondary prophylaxis. Importantly triple positive APS patients (positive for anticradiolipin, anti-ß2 GP I positive and carrying lupus anticoagulant) should be treated with vitamin K antagonists while direct oral anticoagulants have been shown to be inferior in terms of risk/benefit. Treatment of obstetric APS is mainly based on low dose aspirin and low molecular heparin. Notably, this treatment should be maintained for 6 weeks after delivery. Thus, serologic findings provide the basis for certain key clinical decisions and require their reliable detection.
-
Literatur
- 1 van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747 . doi:10.1002/art.38098
- 2 Aletaha D, Neogi T, Silman AJ. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-2581 . doi:10.1002/art.27584
- 3 Aringer M, Costenbader K, Daikh D. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151-1159 . doi:10.1136/annrheumdis-2018-214819
- 4 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-1304 . doi:10.1136/annrheumdis-2019-215213
- 5 Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393: 2344-2358 . doi:10.1016/S0140-6736(19)30546-X
- 6 Leuchten N, Bertsias G, Smolen J. et al. Reply. Arthritis Care Res (Hoboken) 2019; 71: 696-697 . doi:10.1002/acr.23558
- 7 Tedeschi SK, Johnson SR, Boumpas DT. et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 634-640 . doi:10.1136/annrheumdis-2018-214685
- 8 Pisetsky DS, Spencer DM, Lipsky PE. et al. Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Ann Rheum Dis 2018; 77: 911-913 . doi:10.1136/annrheumdis-2017-212599
- 9 Bentow C, Fritzler MJ, Mummert E. et al. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 2016; 7: 8 . doi:10.1007/s13317-016-0081-2
- 10 Specker C, Dorner T, Schneider M. Hot topic: direct oral anticoagulants (DOAC) in antiphospholipid syndrome?. Z Rheumatol 2019; 78: 493-494 . doi:10.1007/s00393-019-0657-0
- 11 Dufrost V, Risse J, Reshetnyak T. et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17: 1011-1021 . doi:10.1016/j.autrev.2018.04.009
- 12 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371 . doi:10.1182/blood-2018-04-848333
- 13 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40: 163-171 . doi:10.1055/s-0033-1364185
- 14 Pengo V, Tripodi A, Reber G. et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740 . doi:10.1111/j.1538-7836.2009.03555.x